pancreatic cancer
Conditions
Interventions
S-1 is orally administered on days 1-28 of a 42-day cycle. Administration dose of S-1 is based BSA : BSA<
=1.5m2, 60mg twice daily.
Sponsors
Chigasaki Municipal Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) written informed consent 2) oral intake is possible 3) histologically proven pancreatic ductal carcinoma 4) age: >=70 and =<90 5) no previous treatment (chemotherapy) for pancreatic cancer 6) presence of measurable lesion 7) adequate hematologic, hepatic, renal, and cardiac function 8) Karnofsky Performance status: >=50 9) expected more than 8 weeks survival
Exclusion criteria
Exclusion criteria: 1) severe diarrhea 2) require administration of flucytosine, phenytoin, and warfarin 3) severe pleural effusion, ascites fluid 4) active infection 5) active double cancer 6) active peptic ulcer 7) severe comorbidity (cardiovascular disease, renal disease, liver disease, Intestinal tract paralysis) 8) severe mental disorder 9) drug hypersensitivity 10) possibility of pregnancy or patient's hope to be pregnant 11) doctor's decision not to be registered to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, overall survival, progression-free survival | — |
Countries
Japan
Contacts
Public ContactHitoshi Kuriyama
Chigasaki Municipal Hospital Department of Gastroenterology
Outcome results
None listed